Work in this Centre focuses on different aspects of the biology of transformed cells or the stromal cells found in neoplastic foci. Our unifying interest is in understanding the cellular and molecular events which drive tumour progression to the malignant phenotype. We have a particular interest in understanding the nature of the “cross-talk” between epithelial cancer cells and their stromal partners during cancer evolution.
Our centre’s researchers work on different aspects of the biology of transformed cells or the stromal cells found in neoplastic foci. We bring together individuals with a diverse range of expertise in cell biology, molecular biology and pathology to form a synergistic approach to complex biological problems.
Our unifying interest is in understanding the cellular and molecular events which drive tumour progression to the malignant phenotype. We have a particular interest in understanding the nature of the “cross-talk” between epithelial cancer cells and their stromal partners during cancer evolution.
We bring together research scientists and clinicians to work on the research problems, with a focus always on the validation of ideas and observations in clinically-derived material, to ensure that bench-work is oriented toward understanding a “real” phenomenon.
Centre Lead
Deputy Centre Lead
John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ
Professor in Cell Signalling and Cancer Biology
Professor of Cancer Metabolism
Professor of Gastrointestinal Cancer Medicine
Professor of Breast Pathology
Professor of Cellular Oncology
Professor of Liver and Pancreas Surgery
Professor of Tumour Biology
Senior Lecturer
Reader in Cell and Developmental Biology
Lecturer
Senior Lecturer
Clinical Senior Lecturer
Professor Louise Jones at Barts Cancer Institute, Queen Mary University of London, has been elected to the Academy of Medical Sciences. She joins 60 exceptional biomedical and health scientists elected to its prestigious Fellowship.
Grants & Awards 21 May 2026
A more active approach to monitoring and treating people with a rare eye cancer (known as uveal melanoma) that has spread to the liver could help some patients to live longer, according to researchers at Barts Cancer Institute, Queen Mary University of London. The findings, from a retrospective study of the largest UK cohort of patients with this condition to date, offer an encouraging sign of progress in this rare and difficult-to-treat cancer.
Publications 21 January 2026
Scientists have discovered that a single letter change in a gene called PRKCA drives a rare and hard-to-treat brain cancer, chordoid glioma, through an entirely unexpected mechanism. The findings could open up new ways to design targeted treatments for this difficult-to-treat disease, and possibly for other cancers involving the same gene.
General News 7 November 2025